孕妇的压力诱导基因调节:系统性审查和定量证据综合
Monika Wójtowicz-Marzec1, Agnieszka Maria Berendt1, Danuta Zarzycka1
1Department of Pediatrics and Pediatric Nursing, Faculty of Health Sciences, Medical University of Lublin, Lublin, Poland; Department of Integrated Nursing Care, Faculty of Health Sciences, Medical University of Lublin, Lublin, Poland.
Psychoneuroendocrinology
|November 13, 2025
概括
产前压力表明与母体DNA甲基化中的表观遗传变化有关,但这些发现取决于上下文,尚未在临床上适用. 对于可靠的生物标志物,需要更多的研究.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 心理神经内分泌学心理学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
背景情况:
- 产前心理社会压力与不利的母婴结果有关.
- 这些效应可能由应激敏感的内分泌通路和表观遗传调节介导.
- 这项研究研究了产前压力与母亲DNA甲基化 (DNAm) 在关键心理神经内分泌基因之间的联系.
研究的目的:
- 系统地审查和综合有关产前压力和母体DNA甲基化之间的关联的定量证据.
- 在心理神经内分泌基因中识别特定的DNA甲基化位点,这些基因因因产前压力而改变.
- 评估这些关联的证据的确定性.
主要方法:
- 进行了一项PROSPERO注册的,与PRISMA结合的系统审查,并进行了定量证据综合 (QES).
- 搜索涵盖了2014-2025年,包括观察性研究和使用血液和唾液/口腔样本的一项随机试验.
- 效应被标准化 (Hedges' g) 并使用随机效应模型进行聚合;多层模型和强大的差异估计处理了依赖数据. 偏差风险和确定性使用ROBINS-I/RoB 2和GRADE进行评估.
主要成果:
- 对NR3C1外子1F的发现在组织,时间和压力域之间异质,排除了单个聚合估计.
- 对于FKBP5内核7,较低的DNAm与更大的创伤/PTSD负担相关 (SMD = -0.36).
- 单项研究对比表明,根据压力和基因型,其他FKBP5和OXTR位点的DNAm变化各不相同. 绝对DNAm差异通常很小 (<1-3%). 总体而言,证据的确定性低至非常低.
结论:
- 产前压力与外围母体组织中可检测的,取决于背景的表观遗传变异有关.
- 目前没有特定的DNA甲基化部位 (CpG) 或区域为临床应用准备好.
- 未来的进展需要区域和组织匹配的复制,与细胞类型调整协调的应激表型,以及对元分析的公开报告.
更多相关视频
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.2K
05:17Author Spotlight: Enhancing the Offspring Health in Rats with Maternal Exercise During Pregnancy
Published on: April 5, 2024
1.3K
相关概念视频
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
